US 12157035 — Patent Expiration

METHOD AND SYSTEM FOR MONITORING AND FEED-BACKING ON EXECUTION OF PHYSICAL EXERCISE ROUTINES

Shareable link — bookmark or send to anyone

www.patentreply.ai/tools/patent-expiration/US12157035

Important: This calculator does not include patent term extension under 35 U.S.C. § 156, which may apply to certain drug, biologic, animal drug, and medical device patents.

Learn how PTE is calculated

US 12157035

Method And System For Monitoring And Feed-backing On Execution Of Physical Exercise Routines

Medium Confidence

Application No. 18313338

January 26, 2032

5y 156d remaining

Earliest effective filing

Jan 26, 2012

+ 20 years

Jan 26, 2032

PTA +0d

Jan 26, 2032

No TD

—

Final

Jan 26, 2032

This calculation includes Patent Term Adjustment (PTA) under 35 U.S.C. §154(b). Patent Term Extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.

Calculation Details

Base Term Calculation

Filing Date

May 7, 2023

Earliest Effective Filing

January 26, 2012

Issue Date

December 3, 2024

PTA

0 days

Base Expiry (before PTA)

January 26, 2032

January 26, 2012 + 20 years = January 26, 2032

Continuation of application 15997405, filed Jun 4, 2018, issued as US 11745055

Continuation of application 14671216, filed Mar 27, 2015, issued as US 9987520

Continuation of application 13359273, filed Jan 26, 2012, issued as US 9011293

Continuation of application 14671216, filed Mar 27, 2015, issued as US 9987520

Continuation of application 13359273, filed Jan 26, 2012, issued as US 9011293

PRO

61436402 — Provisional — not used for base term

PRO

61436402 — Provisional — not used for base term

PRO

61436402 — Provisional — not used for base term

PRO

61436402 — Provisional — not used for base term

Terminal Disclaimer Analysis

TD Approved

1 approved, 1 filed

Who owns this patent?

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.